taxotere | malecare.org

On the Horizon- Patupilone in Patients with Metastatic Castration-Resistant Prostate Cancer who have Progressed after Docetaxel – A Phase II Study

Once we have failed docetaxel therapy (chemo therapy) we have very few options available to control advanced prostate cancer. There is a recnt report about a clinical trial using a new potential drug, Patupilone. Patupilone has shown some evidence that it exhibits a limited positive effect in the pre-clinical setting in taxane resistant models of [...]

By Malecare|2017-10-19T10:54:41-04:00August 14th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, On The Horizon, Uncategorized, Understanding APC|0 Comments

Chemo Brain – Yes, Prostate Cancer Survivors Do Suffer From It

Today’s New York Times has published another of its fantastic articles about cancer and coping with cancer. Today’s article, written by Jane Brody, discusses chemo brain. Until a short time ago, many doctors denied that it even existed, but today it is pretty much accepted as being real. One is said to suffer from chemo [...]

By Malecare|2017-10-19T10:54:43-04:00August 11th, 2009|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, General Information, Hormone Therapy, How We Live, Me, Personal Experiences, Uncategorized, Understanding APC|0 Comments

Mitoxantrone Plus Prednisone – A Possible Fallback After Taxotere Failure

Men with metastatic hormone-refractory prostate cancer (mHRPC) who become docetaxel-refractory (no longer responsive to docetaxel therapy have no approved second line chemotherapy available. One could say that they have reached the proverbial brick wall. Where to go and what to do is not at all clear. Most of us do not want to just roll [...]

By Malecare|2017-10-19T10:54:46-04:00July 20th, 2009|Advanced Prostate Cancer, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, End-Of-Life, How We Live, Uncategorized, Understanding APC|0 Comments

Increased Levels of C-Reactive Protein is Confirmed to Limit Survival

A presentation at the ASCO conference in Florida reconfirmed the fact that increased levels of C-reactive protein (CRP) is associated with adverse outcomes (earlier death) in men with castration-resistant prostate cancer (CRPC) treated with docetaxel (taxotere). The study analyzed the baseline serum samples from 119 castrate resistant (CRPC) men enrolled in 6 phase I or [...]

By Malecare|2009-06-22T09:53:05-04:00June 22nd, 2009|Advanced Prostate Cancer, General Information, Research, Uncategorized, Understanding APC|0 Comments

Increased Survival Demonstrated in a Phase II Trial of OGX-011

Results from a randomized phase II study presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting indicates there might be a new drug on the horizon for men with advanced prostate cancer. OncoGenex Pharmaceuticals drug known as OGX-011 extended the survival of patients with advanced prostate cancer by almost seven months in [...]

By Malecare|2017-10-19T10:55:15-04:00May 31st, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Provenge, Uncategorized|0 Comments